proof of concept

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

More than 10.000 documents for proof of concept

- Cannabis Science Initiates Hiv Tat Anti-Viral Drug Development Program; Cs-Tati-1 Lead Hit Discovery Commenced for Pre-Clinical Proof of Concept Development
The Company will Focus on Pre-Clinical Facilitation of Target Validation Proof of Concept of TAT Inhibition, Structure Activity Relationships for Compound Identification Based on Fragment Lead Discovery through Collaborations with Leading Scientific Institutions Cannabis Science Inc.
- Business Wire
- June 05, 2012
- Cancer Therapeutics Reveals Proof of Concept for Second Development Drug
At the same time completes development of new HTS platform Both posters at EACR conference, Barcelona, Spain
- Business Wire
- July 04, 2012
- Ipsen to initiate a proof-of-concept study with tasquinimod in additional cancer indications.
Tasquinimod's unique mode of action potentially attractive in multiple malignant tumors PARIS -- Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN;...
- Business Wire
- October 19, 2012

- Ipsen to Initiate a Proof-of-Concept Study with Tasquinimod in Additional Cancer Indications
Tasquinimod's unique mode of action potentially attractive in multiple malignant tumors For further information:
- Business Wire
- October 19, 2012
- Cellerant Announces Publication Demonstrating Significant Survival Benefits and Preclinical Proof of Concept with Myeloid Progenitors As Radiation Countermeasure
Cellerant Therapeutics Inc. Jun Yoon, 650-232-2122
- Business Wire
- May 14, 2012
- Rosa and FOCUS-IP Announce Strategic Alliance for Enhancing Proof-of-Concept Drug Development and Licensing Opportunities.
SAN CARLOS, Calif. -- Rosa & Co. LLC (www.rosaandco.com) today announced that it has formed a strategic scientific alliance with FOCUS-IP (www.focus-i...
- Business Wire
- May 05, 2011
- Acorda Therapeutics Announces Initiation of Ampyra(R) Proof-of- Concept Study in Patients with Post-Stroke Deficits
Acorda Therapeutics Jeff Macdonald, 914-347-4300 ext. 4232
- Business Wire
- June 12, 2012
- ViroStatics Demonstrates Clinical Proof of Concept for Dual Antiviral Anti-Hyperactivation AV-HALT Drugs.
Phase 2 Study Results in HIV-infected Individuals Presented at the Conference on Retroviruses and Opportunistic Infections BOSTON -- An analysis of ...
- Business Wire
- March 01, 2011
- Merck to Initiate Proof-of-Concept Study of Posaconazole for Chronic Chagas Disease, Recognized by WHO as One of the World's Neglected Tropical Diseases.
WHITEHOUSE STATION, N.J. -- Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral an...
- Business Wire
- June 24, 2010
- Acorda Therapeutics Announces Initiation of AMPYRA[R] Proof-of-Concept Study in Patients with Post-Stroke Deficits.
HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in a proof-of-concept study explo...
- Business Wire
- June 12, 2012